Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
Kathryn Lurain(The Ohio State University), Robert Yarchoan(National Cancer Institute), Thomas S. Uldrick(Regeneron (United States)), Anaida Widell(AIDS United), Richard F. Ambinder(Johns Hopkins University), James L. Gulley(National Cancer Institute), Ramya Ramaswami(National Cancer Institute), Irene Ekwede(AIDS United), Hao‐Wei Wang(Fu Jen Catholic University), Jomy George(National Institutes of Health), Martin A. Cheever(Johns Hopkins University), Priscila Gonçalves(The Barbara Ann Karmanos Cancer Institute), Ralph Mangusan(AIDS United)
Cited by 69
Related Papers
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
|Clinical Cancer Research|2009|1.4k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
|Genes & Development|2010|744
Hodgkin lymphoma: A review and update on recent progress
|CA A Cancer Journal for Clinicians|2017|479